DBVT_OUT_1 [2025-04-14 13:25:35 -0400] 4228 Bytes | 1100 tokens | Cum: 1100 tkns (13.75% of 8k)
==========================================================================

We need a winner today and it's already 1:25:34 PM on Mon Apr 14, 2025 -0400 ... So let's find out if DBV Technologies S.A. (DBVT) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 7.5500 up from 7.3200. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: DBV Technologies S.A. (DBVT)
IPO: 2014-10-22 (10 Years Ago)
Market Cap: $202,565,251
Shares Outstanding: 136,950,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Here’s the first list of news for DBV Technologies S.A.:

C1 - Today 08:50AM - Here's What Could Help DBV Technologies (DBVT) Maintain Its Recent Price Strength
C2 - Apr-11-25 04:30PM - DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
C3 - Apr-10-25 07:00AM - 3 Biopharmaceutical Stocks Bucking the Sell-Off
C4 - Mar-27-25 10:30PM - DBV Technologies Announces Financing of up to $306.9 Million ( 284.5 Million) to Advance Viaskin Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
C5 - Mar-24-25 03:09AM - DBV Now Plans BLA Submission For Viaskin Peanut Patch In Children 4 - 7-years-old In H1, 2026
C6 - Mar-24-25 03:09AM 02:30AM - DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin Peanut Patch in 4 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results...
C7 - Feb-25-25 04:01PM - DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
C8 - Jan-13-25 04:05PM - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: DBV Technologies S.A. (DBVT).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

DBVT_OUT_3 [2025-04-14 13:25:37 -0400] 459 Bytes | 147 tokens | Cum: 1249 tkns (15.61% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**Here's What Could Help DBV Technologies (DBVT) Maintain Its Recent Price Strength**
Date: Today 08:50AM
Source: (Zacks)
URL: /news/23256/heres-what-could-help-dbv-technologies-dbvt-maintain-its-recent-price-strength

**No additional content available.**

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DBVT_OUT_5 [2025-04-14 13:25:38 -0400] 901 Bytes | 274 tokens | Cum: 1632 tkns (20.40% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-10T06:00:00Z - 3 Biopharmaceutical Stocks Bucking the Sell-Off...
A2 - 2025-04-08T06:07:30Z - DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com...
A3 - 2025-03-31T12:56:29Z - Market Outlook: What To Expect This Week - eBay (NASDAQ:EBAY), American International Gr (NYSE:AIG)...
A4 - 2025-03-30T06:07:33Z - DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com...
A5 - 2025-03-28T18:10:21Z - DBV Technologies Stock Jumps Nearly 40% On Financing Of Up To $306.9 Mln...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

DBVT_OUT_7 [2025-04-14 13:25:39 -0400] 1098 Bytes | 284 tokens | Cum: 1918 tkns (23.97% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**3 Biopharmaceutical Stocks Bucking the Sell-Off**Date: 2025-04-10Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/stock-ideas/3-biopharmaceutical-stocks-bucking-the-sell-off/Alumis is set to benefit from a high-profile merger, and DBV and Corcept both have promising drug candidates that are likely moving toward commercialization.

With tariffs sending markets reeling in the first days of the second quarter -- the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025 -- investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market.

Three biopharmaceutic

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DBVT_OUT_9 [2025-04-14 13:25:40 -0400] 1098 Bytes | 279 tokens | Cum: 2199 tkns (27.49% of 8k)
==========================================================================

Showing A1 (chunk 2 of 6): als firms -- Alumis NASDAQ: ALMS, DBV Technologies S.A. NASDAQ: DBVT, and Corcept Therapeutics Inc. NASDAQ: CORT -- have staged significant rallies in 2025 that have either been unaffected by the market's recent seesawing or that remain up by a wide margin year-to-date as of Apr. 7. There is, of course, no telling whether these companies will have the momentum to keep these rallies going over the short or long term, but they nonetheless merit additional consideration.

Alumis is a clinical-stage biopharma firm developing treatments for immune-mediated disease. It has achieved success with tyrosine kinase 2 (TYK2) inhibitors such as its ESK-001, which is being commercialized in Japan by Kaken Pharmaceutical Co., Ltd. for dermatology indications. ESK-001 also has potential as a treatment for certain rheumatological and gastrointestinal diseases. Alumis' A-005, another TYK2 inhibitor, has r

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DBVT_OUT_11 [2025-04-14 13:25:41 -0400] 948 Bytes | 295 tokens | Cum: 2496 tkns (31.20% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-11T20:30:00Z - DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
B2 - 2024-11-11T21:30:00Z - DBV Technologies Announces Plan to Implement ADS Ratio Change
B3 - 2024-10-22T20:45:00Z - DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe
B4 - 2024-10-22T20:45:00Z - DBV annonce des avancées règlementaires positives pour le patch Viaskin® Peanut aux États-Unis et en Europe
B5 - 2024-10-18T20:30:00Z - DBV Technologies to Participate in Upcoming ACAAI 2024 Congress
B6 - 2024-10-18T20:30:00Z - DBV Technologies participera au prochain congrès de l'ACAAI 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DBVT_OUT_13 [2025-04-14 13:25:44 -0400] 736 Bytes | 199 tokens | Cum: 2697 tkns (33.71% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/11/3060348/0/en/DBV-Technologies-announces-filing-of-2024-Annual-Report-on-Form-10-K-and-Universal-Registration-Document.htmlDBV Technologies, a biopharmaceutical company, announced the filing of its 2024 Annual Report and Universal Registration Document, which include audited financial statements and other regulatory filings.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DBVT_OUT_15 [2025-04-14 13:25:45 -0400] 1082 Bytes | 272 tokens | Cum: 3056 tkns (38.20% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-11 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read this discussion and analysis of our financial condition and CONS results of operations together with the CONS financial statements, related notes and o...

S3 - 2025-03-31 8-K Item1.01. Entry into a Material Definitive Agrmt

Private Placement and Securities Purchase Agrmts

On March 27, 2025, DBV Technologies S.A. (the Company) entered into securities purchase agreements (together, the Securities Purchase Agrmts) with the investors named ...

S5 - 2025-03-24 8-K Item2.02. Results of Oper and Fin Cond

On March 24, 2025, DBV Technologies S.A. (the Company) issued a press release announcing preliminary unaudited financial results for the fiscal year ended December 31, 2024. These amounts are unaudited and preliminary, are ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

DBVT_OUT_17 [2025-04-14 13:25:48 -0400] 1098 Bytes | 227 tokens | Cum: 3285 tkns (41.06% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read this discussion and analysis of our financial condition and consolidated results of operations together with the consolidated financial statements, related notes and other financial information included in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including statements of our plans, objectives, expectations and intentions, contain forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the Risk Factors section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DBVT_OUT_19 [2025-04-14 13:25:49 -0400] 1098 Bytes | 242 tokens | Cum: 3600 tkns (45.00% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): discussion and analysis. Please also see the section titled Forward-Looking Statements.

Overview

We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskins mechanism of action is novel and differentiated. Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the bo

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

DBVT_OUT_21 [2025-04-14 13:25:54 -0400] 6364 Bytes | 1714 tokens | Cum: 5316 tkns (66.45% of 8k)
==========================================================================

This is our set of metrics for DBV Technologies S.A..
Please analyze the numbers.

+---------------------+------------------------+------------------------+-------------------------+
| Volume: 44,005 | Perf Month: 55.03% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+------------------------+------------------------+-------------------------+
| Avg Volume: 401.21K | Perf Quarter: 39.56% | Short Float: 2.06% | ROE: -135.93% |
+---------------------+------------------------+------------------------+-------------------------+
| Rel Volume: 0.19 | Index: - | Short Ratio: 1.40 | ROI: -186.50% |
+---------------------+------------------------+------------------------+-------------------------+
| RSI (14): 63.83 | Market Cap: 206.42M | Short Interest: 0.56M | Sales Surprise: -45.45% |
+---------------------+------------------------+------------------------+-------------------------+
| ATR (14): 0.79 | Shs Outstand: 27.34M | Beta: -0.63 | EPS Surprise: -9.09% |
+---------------------+------------------------+------------------------+-------------------------+
| SMA20: 24.36% | Shs Float: 27.32M | Sales Q/Q: - | P/E: - |
+---------------------+------------------------+------------------------+-------------------------+
| SMA50: 49.68% | Inst Own: 9.76% | Sales past 5Y: 0.00% | Earnings: Mar 24 BMO |
+---------------------+------------------------+------------------------+-------------------------+
| SMA200: 80.74% | Insider Own: 0.07% | Employees: - | |
+---------------------+------------------------+------------------------+-------------------------+
| Perf Week: 1.48% | Insider Trans: -16.77% | Debt/Eq: 0.55 | |
+---------------------+------------------------+------------------------+-------------------------+

The next section covers any insider trading by DBV Technologies S.A. officers or majority shareholders (if available).

No transactions recorded.

Inside Trans: DBV Technologies S.A. (DBVT) by BAKER BROS. ADVISORS LP (Unknown Title) on 2025-03-27
- First Pre-Funded Warrant: 2299656 shares at $N/A (I)
- First Pre-Funded Warrant: 25005240 shares at $N/A (I)
- BS Warrant: 2299656 shares at $N/A (I)
- BS Warrant: 25005240 shares at $N/A (I)

Inside Trans: DBV Technologies S.A. (DBVT) by Mohideen Pharis (Chief Medical Officer) on 2025-01-30
- Ordinary Shares: 600 shares at $0.85 (D) Footnote: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 12515000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -102089000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 7.55
Average Volume: 1141458.86
30-Day High: 7.86
30-Day Low: 3.91

[Detailed Financials: Q3 2024]
- Total Assets: $93,055,000.0
- Total Liabilities: $39,021,000.0
- Total Equity: $54,034,000.0
- Current Assets: $68,759,000.0
- Current Liabilities: $30,913,000.0

[Income Statement: Q3 2024]
- Revenue: $1,072,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.32

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-22,559,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $114,190,000.0
- Total Liabilities: $35,095,000.0
- Total Equity: $79,095,000.0
- Current Assets: $89,958,000.0
- Current Liabilities: $27,381,000.0

[Income Statement: Q2 2024]
- Revenue: $1,161,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.34

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-34,415,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of DBV Technologies S.A. (DBVT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about DBV Technologies S.A..

2) MARKET_SCORE[]
This conversation was initiated because DBVT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for DBVT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, DBVT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect DBVT to increase 50% from its current price of $7.55, say: PRICE_TARGET[11.32]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of DBV Technologies S.A..

11) ETHICAL_RATING[]
Rate DBV Technologies S.A.’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

DBVT_IN_23 [2025-04-14 13:25:54 -0400] 126 Bytes | 29 tokens | Cum: 5525 tkns (69.06% of 8k)
==========================================================================

====================================
[2025-04-14 13:25:54] # Analysis Completed
Elapsed Time: 20.25 seconds